6.7 C
London
Thursday, December 19, 2024
HomeHealth3-drug combo improves survival period for bowel cancer patients

3-drug combo improves survival period for bowel cancer patients

Related stories

J&K police release list of seized assets used for terrorism

Jammu, Feb 16 : The police in Jammu and...

Israel says 4 mln citizens vaccinated against Covid-19

Jerusalem, Feb 17 : Israeli officials announced that some...

Hungary to receive first shipment of Chinese vaccines

Beijing, Feb 17 : A Hungarian cargo plane loaded...

London: A targeted three-drug combination therapy resulted in median overall survival of nine months for patients with advanced bowel cancer compared to 5.4 months for current standard-of-care treatment, showed the results of a phase-3 clinical trial.
The data suggested that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw. Metastatic cancer can spread from one organ to another.
BRAF mutations are estimated to occur in up to 15 per cent of patients with metastatic colorectal cancer, with V600E being the most common BRAF mutation and representing a poor prognosis for these patients.
“This study builds on a decade of research into the tumour biology of BRAF-mutated colorectal cancer, and reflects a rationale combination to address the vulnerabilities unique to this tumour,” said principal investigator Scott Kopetz, Associate Professor at the University of Texas MD Anderson Cancer Center in the US.
“We are encouraged to see a meaningful improvement in outcomes with this new regimen for our patients,” Kopetz added.
The international study was a multi-institutional collaboration with over 200 centres worldwide.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories